- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01591668
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
Arkansas
-
Little Rock, Arkansas, Förenta staterna, 72211
- Woodland International Research Group
-
-
Florida
-
DeLand, Florida, Förenta staterna, 32720
- Avail Clinical Research, LLC
-
Orlando, Florida, Förenta staterna, 32809
- Orlando Clinical Research Center
-
-
Missouri
-
Kansas City, Missouri, Förenta staterna, 64131
- Kansas City Gastroenterology and Hepatology
-
-
New Jersey
-
Berlin, New Jersey, Förenta staterna, 08009
- Comprehensive Clinical Research
-
Willingboro, New Jersey, Förenta staterna, 08046
- CRI Worldwide, LLC
-
-
New York
-
New York, New York, Förenta staterna, 10019
- Clinilabs
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19139
- CRI Worldwide, LLC
-
-
Texas
-
San Antonio, Texas, Förenta staterna, 78215
- Alamo Medical Research
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84106
- Lifetree Clinical Research
-
-
-
-
-
Santurce, Puerto Rico, 00909
- Fundacion De Investigacion de Diego
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Males and Females 18-65 years old
- Chronic HCV infection for at least 6 months, treatment naive
- HCV Viral load > 100,000 IU/mL at Screening
- Monoinfection with HCV 1 genotype
- Hepatitis B surface antigen negative
- Screening ECG without clinically significant abnormalities
- BMI 18-33 kg/m^2
- Creatinine clearing > 70 mL/min
- Negative pregnancy test at screening
Exclusion Criteria:
- Pregnant or lactating subjects
- Co-infection with hepatitis B virus (HBV) or HIV
- History of Gilberts disease
- Particular abnormal laboratory parameters
- Diagnosis of autoimmune disease, poorly controlled diabetes, significant psychiatric illness, severe chronic obstructive pulmonary disease (COPD), malignancy, hemoglobinopathy, retinal disease, and those who are immunosuppressed
- Evidence of hepatocellular carcinoma
- On-going alcohol abuse
- Positive uring drug screen
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: 0,3 mg GS-9620
|
This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort.
Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg).
Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
|
Experimentell: 1mg GS-9620
|
This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort.
Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg).
Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
|
Experimentell: 2mg GS-9620
|
This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort.
Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg).
Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
|
Experimentell: 4mg GS-9620
|
This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort.
Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg).
Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
|
Experimentell: 0,3 mg GS-9620 QW x 2 doser
|
This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort.
Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
|
Experimentell: 1mg GS-9620 QW x 2 doser
|
This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort.
Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
|
Experimentell: 2mg GS-9620 QW x 2 doser
|
This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort.
Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
|
Experimentell: 4mg GS-9620 QW x 2 doser
|
This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort.
Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Incidence of adverse events in single and multiple doses of GS-9620
Tidsram: Periodically Day 1 to 6 months
|
Assessments include adverse events, laboratory abnormalities, 12-lead ECG abnormalities and interval measurements, and vital sign measurements
|
Periodically Day 1 to 6 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Assessment of plasma drug concentrations of GS-9620 using non-compartmental methods
Tidsram: Day 1 and Day 8
|
Single ascending dose (SAD) cohorts: serial blood samples will be collected on Day 1 at 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 48, and 96 hours post-dose. Multiple ascending dose (MAD) cohorts: serial blood samples will be collected on Day 8 at 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, and 24 hours post-dose. |
Day 1 and Day 8
|
Measurement of pharmacodynamic markers (cytokines and interferon-stimulated genes [ISGs])
Tidsram: Days 1, 2, 3, 5, 8
|
SAD cohorts: Whole blood and serum for pharmacodynamic (PD) assessments (RNA and cytokine analysis) will be drawn on Day 1: Pre-dose and 8-hour Post-dose, Day 2, Day 3, Day 5, Day 8 MAD cohorts: Whole blood and serum for PD assessments (RNA and cytokine analysis) will be drawn on Day 1: Pre-dose and 8-hours Post-dose, Day 2, Day 3, Day 5, Day 8: Pre-dose and 8 hours Post-dose, Day 9, Day 10, Day 12, and Day 15 |
Days 1, 2, 3, 5, 8
|
Reduction of hepatitis C (HCV) RNA viral load from baseline
Tidsram: Screening, Baseline, Day 8 or 15
|
SAD cohorts: HCV viral load will be drawn at Day 1: Pre-dose, Day 2, 3, 5, 8 and both Follow-up Visits. MAD cohorts: HCV viral load will be drawn at Day 1: Pre-dose, Day 2, 3, 5, Day 8: Pre-dose, 9, 10, 15, and both Follow-Up Visits. |
Screening, Baseline, Day 8 or 15
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Matsmältningssystemets sjukdomar
- RNA-virusinfektioner
- Virussjukdomar
- Infektioner
- Blodburna infektioner
- Smittsamma sjukdomar
- Leversjukdomar
- Flaviviridae-infektioner
- Hepatit, Viral, Human
- Enterovirusinfektioner
- Picornaviridae-infektioner
- Hepatit, kronisk
- Hepatit
- Hepatit A
- Hepatit C
- Hepatit C, kronisk
- Anti-infektionsmedel
- Antivirala medel
- Vesatolimod
Andra studie-ID-nummer
- GS-US-243-0102
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Hepatit C
-
Dokuz Eylul UniversityEge UniversityAvslutadMMP9 | TIMP1 | MMP9 -1562 C/T | TIMP1 372 T/CKalkon
-
Tripep ABInovio PharmaceuticalsOkändKronisk hepatit C-virusinfektionSverige
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsIndragenKronisk hepatit C-virusinfektionIsrael
-
Hadassah Medical OrganizationOkändKronisk hepatit C-virusinfektionIsrael
-
Johann Wolfgang Goethe University HospitalAvslutad
-
Trek Therapeutics, PBCAvslutadKronisk hepatit C | Hepatit C genotyp 1 | Hepatit C (HCV) | Hepatit C virusinfektionFörenta staterna, Nya Zeeland
-
Trek Therapeutics, PBCAvslutadKronisk hepatit C | Hepatit C (HCV) | Hepatit C genotyp 4 | Hepatit C virusinfektionFörenta staterna
-
Beni-Suef UniversityAvslutadKronisk hepatit C-virusinfektionEgypten
-
Humanity and Health Research CentreBeijing 302 HospitalAvslutadKronisk hepatit C-infektionKina
-
Meir Medical CenterAvslutadUtveckla ny teknik för att mäta C/D-förhållande från digitala stereooptiska skivbilder | Intraobservatörsreproducerbarhet av C/D-mätningar | Interobservatörsvariabilitet av C/D-mätningar
Kliniska prövningar på Single Ascending Dose Cohorts GS-9620
-
Gilead SciencesAvslutadHepatit BKorea, Republiken av, Förenta staterna, Kanada, Australien, Nya Zeeland
-
Gilead SciencesAvslutadHepatit B | HBVKorea, Republiken av, Förenta staterna, Kanada, Australien, Nya Zeeland